Concepedia

Bo Lan

BL

Statistics

Publications

25

Citations

1.3K

H-Index

17

Active since

2017

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

National Cancer Center

Cancer Hospital of Huanxing Chaoyang District Beijing

Jiangsu Hengrui Medicine (China)

Peking University Cancer Hospital

Bo Lan is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2017–2024

25

Publications

25

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Fei Ma, Qiao Li, Shanshan Chen et al. · Journal of Clinical Oncology · 2017 · 234 citations

, , +17

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

Jing Huang, Binghe Xu, Hongnan Mo et al. · Clinical Cancer Research · 2018 · 217 citations

, , +17

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Hongnan Mo, Jing Huang, Jiachen Xu et al. · British Journal of Cancer · 2018 · 156 citations · Full text

, , +17

Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer

Zitong Zhao, Li Lin, Peina Du et al. · Theranostics · 2019 · 99 citations · Full text

, , +17

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Qiao Li, Xiuwen Guan, Shanshan Chen et al. · Clinical Cancer Research · 2019 · 93 citations

, , +17

1–5 of 25